Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025 Expect to present interim analysis from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing ADVANCED-2 trial in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support now expected by year-end 2025 Cash, cash equivalents and investments of approximately $134 million as of September 30, 2025, expected to support planned operations into mid-2027NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results...

Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA) Completed $15 million registered direct offering and $125 million private placement with potential for up to an additional $165 million upon full warrant exercise Completed pivotal phase 3 DRAGON trial in Stargardt disease (STGD); final topline data expected in Q4 2025 China’s NMPA has agreed to accept New Drug Application with priority review for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results of DRAGON trial UK’s MHRA has agreed to accept Conditional Marketing Authorization application for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results of DRAGON trial Conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ETSAN DIEGO, Nov. 10, 2025...

Forward contract cover locked in for 100% of 2025, 96% of 2026, and 74% of 2027. Maximizing strategic optionality while also returning capital to shareholders. Annualized dividend to increase to $2.50 per Class A Common Share. ATHENS, Greece, Nov. 10, 2025 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE: GSL) (the “Company”, “Global Ship Lease” or “GSL”), an owner of containerships, announced today its unaudited results for the three and nine-month periods ended September 30, 2025. Third Quarter of 2025 and Year to Date Highlights and Other Recent Developments3Q 2025 operating revenue of $192.7 million; up 10.7% on 3Q 2024. 9M 2025 operating revenue of $575.5 million; up 8.9% on 9M 2024.3Q 2025 net income available to common shareholders of $92.6 million, or $2.59 Earnings per Share (EPS); up 17.5% on 3Q 2024. 9M 2025 net...

Released positive Definitive Feasibility Study (“DFS”) for the South West Arkansas Project (“SWA Project”) which continues progressing towards a Final Investment Decision (“FID”) Announced Maiden Inferred Resource for the Company’s first project in East Texas (“Franklin Project”) containing the highest reported lithium-in-brine grades in North America Completed upsized $130 million follow-on offering on the back of strong institutional investor demand and an oversubscribed order book, following quarter closeVANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE.A: SLI), a leading near-commercial lithium company, today announced its financial and operating results for the three and nine-month periods ended September 30, 2025. “We had a busy...

Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive at least $50 million from cost sharing  Announced positive long-term safety and efficacy data with 1.5 to 2 years of follow-up from the Phase 1/2 PRISM clinical trial in wet AMD  Completed equity offering providing net proceeds of ~$93 million   Announced up to $11 million equity investment from the Cystic Fibrosis Foundation to accelerate development of 4D-710 for cystic fibrosis into Phase 2   $372 million in cash, cash equivalents and marketable securities as of September 30, 2025, combined with upfront and expected cost sharing from Otsuka partnership and ~$93 million in net proceeds from equity offering, expected to fund currently planned...

Third Quarter 2025 Revenue of $30.3 million; Net Income of $17.0 million OMAHA, Neb., Nov. 10, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus”), a leading self-custodial cryptocurrency platform, today announced its unaudited results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights (Unaudited)In USD millions, except percentages Q3 2025 Q3 2024   % ChangeRevenue   $30.3     $20.1   51 %Technology, development and user support   17.0     11.3   50 %General and administrative   14.9     8.5   75 %(Gain) loss on digital assets, net   (21.0 )   0.4   (5,350 %)Net income   17.0     0.8   2,025 %                 In addition, the company announced earlier today that it has acquired Grateful, a stablecoin payments orchestrator for merchants...

Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in China Establised commercial leadership within excutive team with appointment of Brent S. Rice as Chief Commercial Officer Cash and investments of $305.4 million as of September 30, 2025 expected to fund operations into mid-2027NEWTOWN SQUARE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: “AVBP”), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30, 2025, and highlighted recent Company progress. “Our...

-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine– -CASGEVY® momentum accelerating; nearly 300 patients have been referred to Authorized Treatment Centers (ATCs), approximately 165 patients have completed their first cell collection and 39 have received infusions across all regions; Vertex expects clear line of sight to over $100 million in total CASGEVY revenue this year and significant growth expected in 2026- -Pediatric development of exa-cel is advancing in SCD and TDT, with enrollment in two global Phase 3 studies completed; initial data will be presented at the upcoming American Society of Hematology (ASH) annual meeting- -Clinical trials ongoing for CTX112™, targeting...

CONTINUED GROWTH AND TRANSFORMATIONAL ACQUISITION RESULT IN EXPANSION TO OVER 5.7 MILLION CONSUMERS(1) SERVED AND $6.6 BILLION IN MANAGED RECEIVABLES(2) ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (Atlanticus, the Company, we, our or us), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced its financial results for the third quarter ended September 30, 2025. An accompanying earnings presentation is available in the Investors section of the Company’s website at www.atlanticus.com or by clicking here. Financial and Operating Highlights Third Quarter 2025 Highlights (all comparisons to the Third Quarter 2024)Completed acquisition of Mercury Financial LLC (“Mercury”)...

– Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 –  – Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration – – Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 – LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2025 financial and operating results. “Voyager continues to seek out the optimal modalities for each neurotherapeutic target we pursue. During the third quarter, we shared initial preclinical data on our Voyager NeuroShuttle, a nonviral delivery platform with differentiated...